Phio up on promising results from cancer therapy platform study

Phio Pharmaceuticals

16/09/2021 13:43

** Shares of drug developer  PHIO.O  rise 18.3% to $2.33
premarket
    ** PHIO presents data from a new study showing its therapy
platform, INTASYL, generated durable anti-tumour responses in
mice  urn:newsml:reuters.com:*:nPnb4fldNa
    ** Says mice showing complete cure of tumors after treatment
were rechallenged by implanting cancerous liver cells at a
different location to the previous tumor 
    ** All of the rechallenged mice previously cured after
treatment with the platform were cured again without requiring
further treatment, says PHIO
    ** Up to 83% of the animals treated with the platform showed
no signs of cancer when treated at low doses- co
    ** Co presented the results at the European Society of
Medical Oncology (ESMO) Congress 2021
    ** PHIO had fallen 26.8% YTD, up to the last close

 (Reporting by Amruta Khandekar)
 ((Amruta.Khandekar@thomsonreuters.com;))